Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $1.17 billion. The enterprise value is $1.36 billion.
Important Dates
The last earnings date was Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 44.93 million shares outstanding. The number of shares has decreased by -15.61% in one year.
| Current Share Class | 44.93M |
| Shares Outstanding | 44.93M |
| Shares Change (YoY) | -15.61% |
| Shares Change (QoQ) | -2.29% |
| Owned by Insiders (%) | 0.99% |
| Owned by Institutions (%) | 107.42% |
| Float | 39.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.70 |
| PS Ratio | 1.70 |
| Forward PS | 1.48 |
| PB Ratio | 1.55 |
| P/TBV Ratio | 3.73 |
| P/FCF Ratio | 10.03 |
| P/OCF Ratio | 8.73 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.58, with an EV/FCF ratio of 11.61.
| EV / Earnings | n/a |
| EV / Sales | 1.93 |
| EV / EBITDA | 8.58 |
| EV / EBIT | 19.87 |
| EV / FCF | 11.61 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.83.
| Current Ratio | 2.38 |
| Quick Ratio | 1.79 |
| Debt / Equity | 0.83 |
| Debt / EBITDA | 3.63 |
| Debt / FCF | 5.39 |
| Interest Coverage | 3.67 |
Financial Efficiency
Return on equity (ROE) is -15.57% and return on invested capital (ROIC) is 2.93%.
| Return on Equity (ROE) | -15.57% |
| Return on Assets (ROA) | 2.69% |
| Return on Invested Capital (ROIC) | 2.93% |
| Return on Capital Employed (ROCE) | 5.59% |
| Revenue Per Employee | $893,478 |
| Profits Per Employee | -$161,342 |
| Employee Count | 790 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 1.88 |
Taxes
In the past 12 months, PCRX has paid $20.91 million in taxes.
| Income Tax | 20.91M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +80.28% in the last 52 weeks. The beta is 0.48, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | +80.28% |
| 50-Day Moving Average | 23.61 |
| 200-Day Moving Average | 23.19 |
| Relative Strength Index (RSI) | 65.97 |
| Average Volume (20 Days) | 818,245 |
Short Selling Information
The latest short interest is 6.29 million, so 14.00% of the outstanding shares have been sold short.
| Short Interest | 6.29M |
| Short Previous Month | 5.69M |
| Short % of Shares Out | 14.00% |
| Short % of Float | 15.79% |
| Short Ratio (days to cover) | 8.14 |
Income Statement
In the last 12 months, PCRX had revenue of $705.85 million and -$127.46 million in losses. Loss per share was -$2.81.
| Revenue | 705.85M |
| Gross Profit | 469.43M |
| Operating Income | 68.44M |
| Pretax Income | 100.55M |
| Net Income | -127.46M |
| EBITDA | 158.43M |
| EBIT | 68.44M |
| Loss Per Share | -$2.81 |
Full Income StatementBalance Sheet
The company has $445.86 million in cash and $631.40 million in debt, giving a net cash position of -$185.54 million or -$4.13 per share.
| Cash & Cash Equivalents | 445.86M |
| Total Debt | 631.40M |
| Net Cash | -185.54M |
| Net Cash Per Share | -$4.13 |
| Equity (Book Value) | 757.77M |
| Book Value Per Share | 16.88 |
| Working Capital | 432.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $134.52 million and capital expenditures -$17.46 million, giving a free cash flow of $117.07 million.
| Operating Cash Flow | 134.52M |
| Capital Expenditures | -17.46M |
| Free Cash Flow | 117.07M |
| FCF Per Share | $2.61 |
Full Cash Flow StatementMargins
Gross margin is 66.51%, with operating and profit margins of 9.70% and -18.06%.
| Gross Margin | 66.51% |
| Operating Margin | 9.70% |
| Pretax Margin | -15.10% |
| Profit Margin | -18.06% |
| EBITDA Margin | 22.45% |
| EBIT Margin | 9.70% |
| FCF Margin | 16.59% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 15.61% |
| Shareholder Yield | 15.61% |
| Earnings Yield | -10.86% |
| FCF Yield | 9.97% |
Dividend DetailsAnalyst Forecast
The average price target for PCRX is $30.00, which is 14.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $30.00 |
| Price Target Difference | 14.92% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 6.94% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 1.5 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.5 |
| Piotroski F-Score | 6 |
